MAIA

Handel nachbörslich: 1.36 0.01 +0.74%

MAIA Biotechnology Inc (MAIA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

MAIA Biotechnology Inc Stock (MAIA) Company Profile

MAIA Biotechnology Inc

Healthcare (1111)

Biotechnology (621)

312 416 8592

444 West Lake Street, Suite 1700, Chicago

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MAIA's Discussions on Twitter

Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MAIA MAIA Biotechnology Inc	1.35	84.33M	0	-22.40M	-18.84M	-0.7018
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten

Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)

MAIA Biotechnology Inc (MAIA)

MAIA Biotechnology Inc Stock (MAIA) Company Profile

Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC

MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten

Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday - MarketBeat

MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38 - MSN

BREAKING: TRUMP JUST BOUGHT THIS STOCK! (01ajqP9sss) - fathomjournal.org

MAIA Biotechnology (MAIA) posts narrower Q4 2025 loss than analyst estimates, lifting shares 4.44 percent today.Joint Venture - Newser

MAIA Biotechnology | 8-K: Current report - Moomoo

MAIA Biotechnology opens first U.S. site for lung cancer trial By Investing.com - Investing.com Australia

MAIA Should I Buy - Intellectia AI

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update - MarketBeat

MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com

MAIA Expands THIO-101 Lung Cancer Trial in U.S. - TipRanks

MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M - TradingView

MAIA Biotechnology Activates First U.S. Site for THIO-101 Phase 2 Trial, Reporting Promising Efficacy in Advanced NSCLC Treatment - Quiver Quantitative

Form 8-KCurrent report - ADVFN

MAIA Biotechnology Activates First U.S. Site for Ongoing - GlobeNewswire

MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan

[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan

MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan

EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn

Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn

Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn

Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn

Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn

Is MAIA Biotechnology (MAIA) Stock Slowing Down | Price at $1.25, Up 4.58%Bullish Pattern - Newser

Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn

MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart

Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times

MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView

MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan

MAIA Biotechnology Expects Recent $33 Million Capital Raise - GlobeNewswire

MAIA Biotechnology (NYSE American: MAIA) plans 2026 virtual shareholder meeting, pay vote - Stock Titan

MAIA Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo

Is MAIA Biotechnology (MAIA) Stock Good for Long Term | Price at $1.29, Down 3.01%Sector Leader - Newser

MAIA Biotechnology Awards Executive Bonuses After Successful Financing - TipRanks

MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan

MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan

MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan

MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan

MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan

MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan

Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo

Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn

MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - TipRanks

Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView — Track All Markets

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times

Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView

Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan

After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan

Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie MAIA